Abbott Laboratories entered into a pricing agreement on Feb. 23, 2026 to issue and sell $20.0 billion of senior notes. The offering consists of $1.0 billion of Floating Rate Notes due 2029, plus fixed-rate notes including $2.25 billion of 3.700% notes due 2029, $2.5 billion of 4.000% notes due 2031, $2.75 billion of 4.300% notes due 2033, $3.75 billion of 4.650% notes due 2036, $2.0 billion of 4.750% notes due 2038, $3.75 billion of 5.500% notes due 2056 and $2.0 billion of 5.600% notes due 2066. Closing is expected March 9, 2026, and Abbott said it plans to use proceeds to help fund its planned acquisition of Exact Sciences, repay certain Exact Sciences debt, pay related fees and expenses, and for general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-020509), on February 26, 2026, and is solely responsible for the information contained therein.